1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ott JJ, Stevens GA, Groeger J and Wiersma
ST: Global epidemiology of hepatitis B virus infection: New
estimates of age-specific HBsAg seroprevalence and endemicity.
Vaccine. 30:2212–2219. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chan YC, Banerjee J, Choi SY and Sen CK:
miR-210: The master hypoxamir. Microcirculation. 19:215–223. 2012.
View Article : Google Scholar :
|
6
|
Giannakakis A, Sandaltzopoulos R, Greshock
J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros
D, Weber BL, et al: miR-210 links hypoxia with cell cycle
regulation and is deleted in human epithelial ovarian cancer.
Cancer Biol Ther. 7:255–264. 2008. View Article : Google Scholar
|
7
|
Zhang Z, Sun H, Dai H, Walsh RM, Imakura
M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, et al:
MicroRNA miR-210 modulates cellular response to hypoxia through the
MYC antagonist MNT. Cell Cycle. 8:2756–2768. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tsuchiya S, Fujiwara T, Sato F, Shimada Y,
Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast
growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428.
2011. View Article : Google Scholar :
|
9
|
Biswas S, Roy S, Banerjee J, Hussain SR,
Khanna S, Meenakshisundaram G, Kuppusamy P, Friedman A and Sen CK:
Hypoxia inducible microRNA 210 attenuates keratinocyte
proliferation and impairs closure in a murine model of ischemic
wounds. Proc Natl Acad Sci USA. 107:6976–6981. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kim HW, Haider HK, Jiang S and Ashraf M:
Ischemic preconditioning augments survival of stem cells via
miR-210 expression by targeting caspase-8-associated protein 2. J
Biol Chem. 284:33161–33168. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hu S, Huang M, Li Z, Jia F, Ghosh Z,
Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, et al:
MicroRNA-210 as a novel therapy for treatment of ischemic heart
disease. Circulation. 122(Suppl 11): S124–S131. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Crosby ME, Kulshreshtha R, Ivan M and
Glazer PM: MicroRNA regulation of DNA repair gene expression in
hypoxic stress. Cancer Res. 69:1221–1229. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cicchillitti L, Di Stefano V, Isaia E,
Crimaldi L, Fasanaro P, Ambrosino V, Antonini A, Capogrossi MC,
Gaetano C, Piaggio G, et al: Hypoxia-inducible factor 1-α induces
miR-210 in normoxic differentiating myoblasts. J Biol Chem.
287:44761–44771. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gong Y, Xu F, Zhang L, Qian Y, Chen J,
Huang H and Yu Y: MicroRNA expression signature for Satb2-induced
osteogenic differentiation in bone marrow stromal cells. Mol Cell
Biochem. 387:227–239. 2014. View Article : Google Scholar
|
15
|
Pulkkinen K, Malm T, Turunen M, Koistinaho
J and Ylä-Herttuala S: Hypoxia induces microRNA miR-210 in vitro
and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially
regulated by miR-210. FEBS Lett. 582:2397–2401. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Alaiti MA, Ishikawa M, Masuda H, Simon DI,
Jain MK, Asahara T and Costa MA: Up-regulation of miR-210 by
vascular endothelial growth factor in ex vivo expanded
CD34+ cells enhances cell-mediated angiogenesis. J Cell
Mol Med. 16:2413–2421. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Donnem T, Fenton CG, Lonvik K, Berg T,
Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM,
et al: MicroRNA signatures in tumor tissue related to angiogenesis
in non-small cell lung cancer. PLoS One. 7:e296712012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu F, Lou YL, Wu J, Ruan QF, Xie A, Guo
F, Cui SP, Deng ZF and Wang Y: Upregulation of microRNA-210
regulates renal angiogenesis mediated by activation of VEGF
signaling pathway under ischemia/perfusion injury in vivo and in
vitro. Kidney Blood Press Res. 35:182–191. 2012. View Article : Google Scholar
|
19
|
Lou YL, Guo F, Liu F, Gao FL, Zhang PQ,
Niu X, Guo SC, Yin JH, Wang Y and Deng ZF: miR-210 activates notch
signaling pathway in angiogenesis induced by cerebral ischemia. Mol
Cell Biochem. 370:45–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Shoji T, Nakasa T, Yamasaki K, Kodama A,
Miyaki S, Niimoto T, Okuhara A, Kamei N, Adachi N and Ochi M: The
effect of intra-articular injection of microRNA-210 on ligament
healing in a rat model. Am J Sports Med. 40:2470–2478. 2012.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Yamasaki K, Nakasa T, Miyaki S, Yamasaki
T, Yasunaga Y and Ochi M: Angiogenic microRNA-210 is present in
cells surrounding osteonecrosis. J Orthop Res. 30:1263–1270. 2012.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Kosaka N, Iguchi H, Hagiwara K, Yoshioka
Y, Takeshita F and Ochiya T: Neutral sphingomyelinase 2
(nSMase2)-dependent exosomal transfer of angiogenic microRNAs
regulate cancer cell metastasis. J Biol Chem. 288:10849–10859.
2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Tadokoro H, Umezu T, Ohyashiki K, Hirano T
and Ohyashiki JH: Exosomes derived from hypoxic leukemia cells
enhance tube formation in endothelial cells. J Biol Chem.
288:34343–34351. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai
H, Liu J, Wang Y, Fu Y and Yang GY: MicroRNA-210 overexpression
induces angiogenesis and neurogenesis in the normal adult mouse
brain. Gene Ther. 21:37–43. 2014. View Article : Google Scholar
|
25
|
Chan SY, Zhang YY, Hemann C, Mahoney CE,
Zweier JL and Loscalzo J: MicroRNA-210 controls mitochondrial
metabolism during hypoxia by repressing the iron-sulfur cluster
assembly proteins ISCU1/2. Cell Metab. 10:273–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Chen Z, Li Y, Zhang H, Huang P and Luthra
R: Hypoxia-regulated microRNA-210 modulates mitochondrial function
and decreases ISCU and COX10 expression. Oncogene. 29:4362–4368.
2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Puisségur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar :
|
28
|
Ying Q, Liang L, Guo W, Zha R, Tian Q,
Huang S, Yao J, Ding J, Bao M, Ge C, et al: Hypoxia-inducible
microRNA-210 augments the metastatic potential of tumor cells by
targeting vacuole membrane protein 1 in hepatocellular carcinoma.
Hepatology. 54:2064–2075. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hong L, Han Y, Zhang H, Zhao Q and Qiao Y:
miR-210: A therapeutic target in cancer. Expert Opin Ther Targets.
17:21–28. 2013. View Article : Google Scholar
|
30
|
Qin Q, Furong W and Baosheng L: Multiple
functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer
Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Leung AK and Sharp PA: MicroRNA functions
in stress responses. Mol Cell. 40:205–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Haybaeck J, Zeller N and Heikenwalder M:
The parallel universe: microRNAs and their role in chronic
hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med
Wkly. 141:w132872011.PubMed/NCBI
|
34
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
36
|
Pineau P, Volinia S, McJunkin K, Marchio
A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and
Dejean A: miR-221 overexpression contributes to liver
tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010.
View Article : Google Scholar :
|
37
|
Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y,
Fu S and Lu L: Serum microRNA-210 as a predictive biomarker for
treatment response and prognosis in patients with hepatocellular
carcinoma undergoing transarterial chemoembolization. J Vasc Interv
Radiol. 25:1279–1287.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Yang W, Sun T, Cao J, Liu F, Tian Y and
Zhu W: Downregulation of miR-210 expression inhibits proliferation,
induces apoptosis and enhances radiosensitivity in hypoxic human
hepatoma cells in vitro. Exp Cell Res. 318:944–954. 2012.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Yang W, Wei J, Sun T and Liu F: Effects of
knockdown of miR-210 in combination with ionizing radiation on
human hepatoma xenograft in nude mice. Radiat Oncol. 8:1022013.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Steinberg F, Zhuang L, Beyeler M, Kälin
RE, Mullis PE, Brändli AW and Trueb B: The FGFRL1 receptor is shed
from cell membranes, binds fibroblast growth factors (FGFs), and
antagonizes FGF signaling in Xenopus embryos. J Biol Chem.
285:2193–2202. 2010. View Article : Google Scholar :
|
41
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angio-genesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
42
|
Albanis E and Friedman SL: Hepatic
fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis.
5:315–334. v–vi. 2001. View Article : Google Scholar : PubMed/NCBI
|
43
|
Huang X, Ding L, Bennewith KL, Tong RT,
Welford SM, Ang KK, Story M, Le QT and Giaccia AJ:
Hypoxia-inducible mir-210 regulates normoxic gene expression
involved in tumor initiation. Mol Cell. 35:856–867. 2009.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Bertrand S, Somorjai I, Garcia-Fernandez
J, Lamonerie T and Escriva H: FGFRL1 is a neglected putative actor
of the FGF signalling pathway present in all major metazoan phyla.
BMC Evol Biol. 9:2262009. View Article : Google Scholar : PubMed/NCBI
|
45
|
Trueb B, Zhuang L, Taeschler S and
Wiedemann M: Characterization of FGFRL1, a novel fibroblast growth
factor (FGF) receptor preferentially expressed in skeletal tissues.
J Biol Chem. 278:33857–33865. 2003. View Article : Google Scholar : PubMed/NCBI
|
46
|
Lu J, Xie F, Geng L, Shen W, Sui C and
Yang J: Potential role of microRNA-210 as biomarker in human
cancers detection: A meta-analysis. Biomed Res Int.
2015:3039872015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|